RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07436741, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer;

    Inclusion criterion 1

  3. Have received blood transfusion treatment, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment;

    Exclusion criterion 2

    Have received any surgery or invasive treatment or operation within 4 weeks before enrollment (except venous catheterization, puncture and drainage, etc.);

    Exclusion criterion 3

  4. Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;

    Inclusion criterion 5

  5. At least one measurable lesion according to RECIST version 1.1;

    Inclusion criterion 7

  6. Known human immunodeficiency virus (HIV) infection;

    Exclusion criterion 16

  7. Women who are pregnant or lactating;

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07436741, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer;
  • 18-75 years old (including 18 and 75 years old);
  • No BRCA1/2 or PALB2 mutation;
  • No previous pancreatic cancer resection, systemic therapy, or local radiation therapy;
  • Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
  • Life expectancy ≥ 6 months;
  • At least one measurable lesion according to RECIST version 1.1;
  • Adequate organ and bone marrow functions;
  • Women of childbearing age need to take effective contraceptive measures.

Exclusion Criteria:

  • With distant metastasis;
  • Have received blood transfusion treatment, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment;
  • Have received any surgery or invasive treatment or operation within 4 weeks before enrollment (except venous catheterization, puncture and drainage, etc.);
  • Allergic to the study drug or any of its adjuvants;
  • Researchers judged clinically significant electrolyte abnormalities;
  • History of serious cardiovascular and cerebrovascular diseases;
  • With active ulcer, intestinal perforation and intestinal obstruction;
  • Uncontrollable malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture according to the judgment of the investigator);
  • Clinically significant electrolyte abnormalities judged by researchers;
  • With active bleeding or obvious evidence of bleeding tendency;
  • Hypertension that cannot be controlled by drugs: systolic blood pressure ≥ 150 mmHg and / or diastolic blood pressure ≥ 100 mmHg;
  • Women who are pregnant or lactating;
  • Urinary protein ≥ ++, or the 24-hour urine protein quantification is greater than 1.0g;
  • Concurrent tumors within 5 years (except treated cervical carcinoma in situ, basal cell carcinoma);
  • Any disease or state that affects the absorption of drugs, or the subject cannot take oral drugs;
  • Known human immunodeficiency virus (HIV) infection;
  • History of clinically significant hepatic disease, including, but not limited to, known hepatitis B virus (HBV) infection with HBV DNA positive (copies ≥1×10\^4/ml or >2000 IU/ml); known hepatitis C virus infection with HCV RNA positive (copies ≥1×10\^3/m); hepatitis and cirrhosis;
  • Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions that makes the subject not suitable for enrolling according to the judgment of the investigator.

Quoted from ClinicalTrials.gov, NCT07436741, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07436741, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07436741